Related references
Note: Only part of the references are listed.Haplotype analysis of beta thalassemia patients in Western Iran
Zohreh Rahimi et al.
BLOOD CELLS MOLECULES AND DISEASES (2009)
Dendrimers Bind Human Serum Albumin
E. Froehlich et al.
JOURNAL OF PHYSICAL CHEMISTRY B (2009)
Acute interstitial nephritis due to deferasirox: a case report
Godela Brosnahan et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2008)
Studies of the interaction between paraquat and bovine hemoglobin
Yan-Qing Wang et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2007)
Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major
C Borgna-Pignatti et al.
BLOOD (2006)
Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis
DJ Pennell et al.
BLOOD (2006)
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia
MD Cappellini et al.
BLOOD (2006)
Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells
H Glickstein et al.
BLOOD (2005)
Medical progress:: β-thalassemia
D Rund et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Effect of metal ions on the interaction between bovine serum albumin and berberine chloride extracted from a traditional Chinese Herb coptis chinensis franch
XF Liu et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2005)
The study on the interaction between human serum albumin and a new reagent with antitumour activity by spectrophotometric methods
H Gao et al.
JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY A-CHEMISTRY (2004)
Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone
AR Cohen et al.
BLOOD (2003)
Role of deferiprone in chelation therapy for transfusional iron overload
AV Hoffbrand et al.
BLOOD (2003)
Iron chelator research: Past, present, and future
TF Tam et al.
CURRENT MEDICINAL CHEMISTRY (2003)
Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia:: a randomised, double-blind, placebo-controlled, dose-escalation trial
E Nisbet-Brown et al.
LANCET (2003)
Crystallization and preliminary X-ray structural studies of hemoglobin A2 and hemoglobin E, isolated from the blood samples of β-thalassemic patients
J Dasgupta et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
Oxygen affinity of hemoglobin regulates O2 consumption, metabolism, and physical activity
T Shirasawa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Natural β-sheet proteins use negative design to avoid edge-to-edge aggregation
JS Richardson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Deferiprone versus deferoxamine in patients with thalassemia major: A randomized clinical trial
A Maggio et al.
BLOOD CELLS MOLECULES AND DISEASES (2002)
Practical management of iron overload
JB Porter
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Pharmacosurveillance and quality of care of thalassaemic patients - A large scale epidemiological survey
R Arboretti et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2001)
ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture
C Hershko et al.
BLOOD (2001)
Benefits and complications of regular blood transfusion in patients with beta-thalassaemia major
D Prati
VOX SANGUINIS (2000)
Deferiprone (L1) induced conformation change of hemoglobin: A fluorescence and CD spectroscopic study
D Chakraborty et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2000)
Share Paper
